S. Gail Eckhardt, MD, discusses the role of regorafenib in colorectal cancer.
S. Gail Eckhardt, MD
Advertisement
Articles by S. Gail Eckhardt, MD
S. Gail Eckhardt, MD, discusses the role of angiogenesis inhibitors for the treatment of metastatic colorectal cancer (mCRC), following the approval of aflibercept.
S. Gail Eckhardt, MD, Professor and Head of the Division of Medical Oncology at the University of Colorado Denver and Health Sciences Center, discusses the wnt pathway and its role in colorectal cancer.
Advertisement
Latest Updated Articles
The Wnt Pathway and its Role in Colorectal CancerPublished: August 28th 2013 | Updated:
Angiogenesis Inhibitors in mCRCPublished: September 20th 2013 | Updated:
The Role of Regorafenib in Colorectal CancerPublished: October 29th 2013 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
